Evotaz

Atazanavir/cobicistat
Combination of
Atazanavir	HIV protease inhibitor
Cobicistat	Cytochrome P450 (CYP3A) inhibitor
Clinical data
Trade names	Evotaz
AHFS/Drugs.com	Professional Drug Facts
License data	US DailyMed: Atazanavir_and_cobicistat;
ATC code	J05AR15 (WHO) ;
Legal status
Legal status	UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Identifiers
CAS Number	2446322-19-4;
KEGG	D10753;

Atazanavir/cobicistat, sold under the brand name Evotaz, is a fixed-dose combination antiretroviral medication used to treat and prevent HIV/AIDS.^[2]^[3] It contains atazanavir and cobicistat.^[2]^[3]^[4] Atazanavir is an HIV protease inhibitor and cobicistat is an inhibitor of cytochrome P450 (CYP) enzymes of the CYP3A family.^[2]

Atazanavir/cobicistat was approved by the Food and Drug Administration (FDA) for medical use in United States in January 2015.^[5]^[6] It was approved for medical use in the European Union in July 2015.^[3]

Medical uses

Atazanavir/cobicistat is indicated for use in combination with other antiretroviral agents for the treatment of HIV‑1 infection in people weighing at least 35 kilograms (77 lb).^[2]^[3]

References

^ "Evotaz 300 mg/150 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). Retrieved 9 July 2021.
^ ^a ^b ^c ^d ^e "Evotaz- atazanavir and cobicistat tablet". DailyMed. Retrieved 25 May 2021.
^ ^a ^b ^c ^d ^e "Evotaz EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 25 May 2021.
^ Crutchley RD, Guduru RC, Cheng AM (2016). "Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection". HIV/AIDS: Research and Palliative Care. 8: 47–65. doi:10.2147/HIV.S99063. PMC 4790521. PMID 27022304.
^ "U.S. Food and Drug Administration Approves Bristol-Myers Squibb's Evotaz (atazanavir and cobicistat) for the Treatment of HIV-1 Infection in Adults" (Press release). Bristol-Myers Squibb. Archived from the original on 2020-08-08. Retrieved 2018-06-28.
^ "Evotaz (atazanavir and cobicistat) Tablet". U.S. Food and Drug Administration (FDA). 15 April 2016. Retrieved 25 May 2021. "Summary Report" (PDF).

External links

"Atazanavir mixture with cobicistat". Drug Information Portal. U.S. National Library of Medicine.

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

Zdroj:https://en.wikipedia.org?pojem=Evotaz
Text je dostupný za podmienok Creative Commons Attribution/Share-Alike License 3.0 Unported; prípadne za ďalších podmienok. Podrobnejšie informácie nájdete na stránke Podmienky použitia.

[1] "Evotaz 300 mg/150 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). Retrieved 9 July 2021.

[Evotaz_FDA_label-2] "Evotaz- atazanavir and cobicistat tablet". DailyMed. Retrieved 25 May 2021.

[Evotaz_EPAR-3] "Evotaz EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 25 May 2021.

[Crutchley_2016-4] Crutchley RD, Guduru RC, Cheng AM (2016). "Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection". HIV/AIDS: Research and Palliative Care. 8: 47–65. doi:10.2147/HIV.S99063. PMC 4790521. PMID 27022304.

[5] "U.S. Food and Drug Administration Approves Bristol-Myers Squibb's Evotaz (atazanavir and cobicistat) for the Treatment of HIV-1 Infection in Adults" (Press release). Bristol-Myers Squibb. Archived from the original on 2020-08-08. Retrieved 2018-06-28.

[6] "Evotaz (atazanavir and cobicistat) Tablet". U.S. Food and Drug Administration (FDA). 15 April 2016. Retrieved 25 May 2021. "Summary Report" (PDF).

[1]

[2]

[3]

[4]

[5]

[6]